Below are our currently enrolling studies for patients with Sjogren’s syndrome.

Sponsor: Bristol-Myers Squibb

Protocol Number: IM011-1069

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren’s Syndrome.

Detailed Information:

Clinicaltrials.gov

To learn more or see if you qualify: Click Here

Sponsor: Resolve Therapeutics

Protocol Number: 132-6

The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are:

  • Does RSLV-132 improve the cardinal symptoms of Sjogren’s including fatigue, dryness and pain?
  • Does RSLV-132 improve the tiredness/fatigue caused by Sjogren’s?
  • What are the blood levels of RSLV-132 over time?
  • What is the immune (antibody) response in the body to RSLV-132?
  • What is the safety profile of RSLV-132?

Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS.

Detailed Information:

Clinicaltrials.gov

To learn more or see if you qualify: Click Here